Dabuzalgron is primarily investigated for its potential in treating anxiety and sleep disorders due to its action as a selective agonist at the benzodiazepine site of the GABA_A receptor. It exhibits anxiolytic and sedative effects with a reduced risk of dependence compared to traditional benzodiazepines, making it a candidate for short-term management of insomnia and generalized anxiety. Its selectivity allows for targeted modulation of GABAergic neurotransmission, which may result in fewer cognitive side effects and less potential for tolerance. Research is ongoing to evaluate its efficacy and safety profile in clinical settings.